secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-09-30T12:52:08+00:00
Accession:  0001178913-26-004666
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Silexion doses first patient in Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer
--------------------------------------------------------------------------------

- First patient dosed at Tel Aviv Sourasky Medical Center (Ichilov) in Israel on September 30, 2026, Silexion announced.
- Phase 2/3 trial evaluates SIL204 plus standard chemotherapy versus chemotherapy alone in unresectable Stage 3 LAPC with confirmed KRAS mutation.
- Trial starts with a safety run-in of about 18 patients, then expands to a randomized cohort of about 166 patients.
- SIL204 uses EUS-guided intratumoral delivery plus subcutaneous abdominal injections; additional Israel and Germany sites are expected to join.
- CEO Ilan Hadar called the dosing a defining operational and clinical milestone for Silexion's lead RNAi program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004666/0001178913-26-004666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004666/zk2636171.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-004666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer